$CSLLY News

Last published 1y ago

1y agoADIA ATNM BPTH CNVIF+12Life Sciences Investor Forum: Now Available for Online ViewingGlobeNewswireNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and
1y agoADIA ATNM BPTH CNVIF+12Life Sciences Investor Forum Agenda Announced for June 11th-12thGlobeNewswireNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is
2y agoCSLLY TVTXTravere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyGlobeNewswireCommittee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is
3y agoCSLLY OTCMOTC Markets Group Welcomes CSL Limited to OTCQXGlobeNewswireNEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX:OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced CSL Limited ((ASX: CSL, OTCQX:CSLLY), a
4y agoCSLLYCSL Plasma Makes $125,000 Donation to American Red Cross for Disaster Relief in U.S. CommunitiesPR NewswireBOCA RATON, Fla., Feb. 22, 2022 /PRNewswire/ -- CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, today announced a $125,000 donation to the American Red Cross to fund disaster relief across communities in the Unit
4y agoCSLLYSeqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine TechnologyPR NewswireSUMMIT, N.J., Feb. 7, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced an investment in a new Research and Development (R&D) facility located in Waltham, Mass. The new facility
4y agoCSLLY QUREFinal Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022PR NewswireKING OF PRUSSIA, Pa., Feb. 4, 2022 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational adeno-ass
4y agoCSLLY GNHAF GNHAYCSL BEHRING AG PUBLISHES OFFER PROSPECTUS ON PUBLIC TENDER OFFER FOR ALL PUBLICLY HELD SHARES OF VIFOR PHARMA LTD.PR NewswireMELBOURNE, Australia and ST. GALLEN, Switzerland, Jan. 18, 2022 /PRNewswire/ -- CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited ((ASX: CSL, OTC:CSLLY), today published the offer prospectus regardin
4y agoCSLLY GNHAFCSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.Business WireRegulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005418/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned sub
4y agoCSLLY QURECSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia BPR NewswireKING OF PRUSSIA, Pa., Dec. 15, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the Committee for Medicinal Products for Human Use (CHMP), the chief scientific body of the European Medicines Agency (EMA) accepted its r
4y agoCSLLYEMA Grants Accelerated Assessment for CSL Behring's Haemophilia B Gene TherapyPR NewswireMARBURG, Germany, Dec. 15, 2021 /PRNewswire/ -- CSL Behring today announced that the European Medicines Agency (EMA) has granted its approval for an accelerated assessment request for etranacogene dezaparvovec Marketing Authorisation Application (MAA).
4y agoCSLLY GNHAFCSL Limited Announces Tender Offer To Acquire Vifor Pharma LtdPR NewswireMELBOURNE, Australia and ST. GALLEN, Switzerland, Dec. 14, 2021 /PRNewswire/ -- CSL Limited Announces Tender Offer To Acquire Vifor Pharma Ltd- Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021- Expands CSL
4y agoCSLLY GNHAFCSL Limited announces tender offer to acquire Vifor Pharma LtdBusiness WireAgreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US$179.25 per share Offer equivalent to CHF167 per share1 Proposed ordinary dividend expected to be declared at AGM of 26 Ap
4y agoCSLLY QUREuniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia BGlobeNewswire~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec ~ ~ Etranacogene
4y agoCSLLYNew Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older AdultsPR NewswireSUMMIT, N.J., Dec. 7, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the relative effectiveness of FLUAD® (Influenza Vaccine, Adjuva
4y agoCSLLYSeqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza VaccinePR NewswireSUMMIT, N.J., Nov. 23, 2021 /PRNewswire/ -- The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.1 As the first-ever
5y agoCSLLYCSL Plasma Opens 300th Plasma Donation Center in United StatesPR NewswireBOCA RATON, Fla., Oct. 26, 2021 /PRNewswire/ -- CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, today announced the opening of its 300th U.S. plasma center, which is located in Greenacres, Florida. CSL Plasma is
5y agoCSLLYSeqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021PR NewswireSUMMIT, N.J., Oct. 19, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal inf
5y agoCSLLYClinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D DayPR NewswireMELBOURNE, Australia and KING OF PRUSSIA, Pa., Oct. 18, 2021 /PRNewswire/ -- During its annual R&D investment briefing earlier today, CSL Limited ((ASX:CSL, OTC:CSLLY) highlighted progress from its novel pipeline that spans six therapeutic areas (immunol
5y agoCSLLYSeqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, Expanding the Age Indication to Include Children as Young as Six MonthsPR NewswireSUMMIT, N.J., Oct. 15, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX: CSL), today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT (Influenza Vac
5y agoCSLLYThe New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to <18 Years of AgePR NewswireSUMMIT, N.J., Oct. 14, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published absolute efficacy data on the company's cell-bas
5y agoCSLLYSeqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza VaccinesPR NewswireSUMMIT, N.J., Oct. 4, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the
5y agoCSLLYSeqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021PR NewswireSUMMIT, N.J., Sept. 29, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced data supporting the effectiveness of both cell-based and adjuvanted seasonal influenza vaccines from
5y agoCSLLYUrban League of Philadelphia Names CSL's Elizabeth Walker to Board of DirectorsPR NewswireKING OF PRUSSIA, Pa. and PHILADELPHIA, Sept. 9, 2021 /PRNewswire/ -- CSL's Global Chief Human Resources Officer Elizabeth Walker has been appointed to the Urban League of Philadelphia's Board of Directors.
5y agoCSLLYCSL Behring Underscores its Commitment to Respiratory Patients with Strong Focus on ResearchPR NewswireHATTERSHEIM AM MAIN, Germany, Sept. 4, 2021 /PRNewswire/ -- At this year's fully virtual International Congress of the European Respiratory Society (ERS 2021), CSL Behring will be hosting a highly significant and topical virtual symposium on 6 Septe
5y agoCSLLYCSL Plasma to Provide Flu Vaccines to U.S. Plasma DonorsPR NewswireBOCA RATON, Fla., Aug. 26, 2021 /PRNewswire/ -- CSL Plasma today announced it will provide influenza (flu) vaccination vouchers to U.S. plasma donors following the completion of two plasma donations made within a calendar month. Beginning Sept. 1, donor
5y agoCSLLYSeqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA)PR NewswireSUMMIT, N.J., Aug. 19, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced plans to accelerate the development of its next generation of messenger RNA (mRNA) vaccine technology, s
5y agoCSLLYThe European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force Has Strongly Recommended Subcutaneous Immunoglobulin (SCIg) for CIDP Maintenance TreatmentPR NewswireKING OF PRUSSIA, Pa., Aug. 9, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force has released an update to its guideline on diagnosis
5y agoCSLLYFDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient ConveniencePR NewswireKING OF PRUSSIA, Pa., Aug. 3, 2021 /PRNewswire/ -- CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug. 30, 2020) for co-packaging of a convenience administra
5y agoCSLLYSeqirus Presents New Safety Data Demonstrating Safety of Cell-Based Seasonal Influenza Vaccine on Pregnancy OutcomesPR NewswireSUMMIT, N.J., July 30, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), presented findings from a new observational safety study conducted in the U.S. that found no unexpected adverse pregnanc
5y agoCSLLYSeqirus Begins Shipping Portfolio of Innovative Vaccines for the 2021/22 U.S. Influenza SeasonPR NewswireSUMMIT, N.J., July 27, 2021 /PRNewswire/ -- Seqirus offers a differentiated portfolio of influenza vaccines, including FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the first and only cell-based quadrivalent influenza vaccine for eligible persons two
5y agoCSLLYSeqirus Co-Authors First Study to Assess Simultaneous Administration of Seasonal Influenza Vaccine and COVID-19 Vaccine CandidatePR NewswireSUMMIT, N.J., June 14, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a division of CSL Limited (ASX: CSL), today announced that the company co-authored the first study to demonstrate the safety, immunogenicity and efficacy pro
5y agoCSLLYHizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP PatientsPR NewswireKING OF PRUSSIA, Pa., June 8, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage under Medicare Part B for the treatment of Chronic In
5y agoCSLLYNew Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 DaysPR NewswireKING OF PRUSSIA, Pa., May 16, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more than 82,000 high-risk patients with recent
5y agoCSLLYLyfebulb and CSL Behring Announce the Winner of the 2021 Transplant Innovation ChallengePR NewswireNEW YORK, May 14, 2021 /PRNewswire/ -- Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a global biotherapeutics leader driven by its promise to save an
5y agoCSLLY QURECSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovecPR NewswireKING OF PRUSSIA, Pa., May 6, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure (NASDAQ:QURE) for etranacogene dezaparvovec (AMT-061), a novel gen
5y agoCSLLY QUREuniQure announces closing of commercialization and license agreement with CSL BehringGlobeNewswireLEXINGTON, Mass. and AMSTERDAM, May 06, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the waiting period under the Har
5y agoCSLLYSeqirus Presents New Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children Six Months Through <4 Years of AgePR NewswireSUMMIT, N.J., May 3, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, presented new Phase 3 clinical data demonstrating that the company's cell-based quadrivalent seasonal influenza vaccine (QIVc) was as safe and immunogenic as a st
5y agoCSLLYHizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) Label Update Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP PatientsPR NewswireKING OF PRUSSIA, Pa., April 29, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid)
5y agoCSLLYSeqirus Publishes New Real-World Evidence Supporting the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Clinical Infectious DiseasesPR NewswireSUMMIT, N.J., April 20, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's MF59® adjuvanted, trivalent influenza vaccine (aTIV) in the peer-reviewed me
5y agoCSLLY TRUMY TYO:4543Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection PlatformPR NewswireLAKEWOOD, Colo. and BOCA RATON, Fla., April 19, 2021 /PRNewswire/ -- Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial